NZ629636A - Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions - Google Patents
Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditionsInfo
- Publication number
- NZ629636A NZ629636A NZ629636A NZ62963613A NZ629636A NZ 629636 A NZ629636 A NZ 629636A NZ 629636 A NZ629636 A NZ 629636A NZ 62963613 A NZ62963613 A NZ 62963613A NZ 629636 A NZ629636 A NZ 629636A
- Authority
- NZ
- New Zealand
- Prior art keywords
- lxr
- disorders
- liver
- receptor
- treatment
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 102000004311 liver X receptors Human genes 0.000 title abstract 3
- 108090000865 liver X receptors Proteins 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000035475 disorder Diseases 0.000 title abstract 2
- 230000002500 effect on skin Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- YINCEGLXYKRXRI-UHFFFAOYSA-N 1-(2-chlorophenyl)-5-[5-(3-methylsulfonylphenyl)-1,3,4-oxadiazol-2-yl]pyrazole-3-carboxylic acid Chemical compound CS(=O)(=O)C1=CC=CC(C=2OC(=NN=2)C=2N(N=C(C=2)C(O)=O)C=2C(=CC=CC=2)Cl)=C1 YINCEGLXYKRXRI-UHFFFAOYSA-N 0.000 abstract 1
- OYXXWUOHGUDTAQ-UHFFFAOYSA-N 2-[4-bromo-5-[4-(3-methylsulfonylphenyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]acetic acid chloromethyl 2-[5-[5-(3-methylsulfonylphenyl)thiophen-2-yl]-3-(trifluoromethyl)pyrazol-1-yl]acetate Chemical compound CS(=O)(=O)C=1C=C(C=CC1)C1=CC=C(S1)C1=CC(=NN1CC(=O)OCCl)C(F)(F)F.BrC=1C(=NN(C1C1=CC=C(C=C1)C1=CC(=CC=C1)S(=O)(=O)C)CC(=O)O)C(F)(F)F OYXXWUOHGUDTAQ-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261606160P | 2012-03-02 | 2012-03-02 | |
| PCT/US2013/028438 WO2013130892A1 (en) | 2012-03-02 | 2013-02-28 | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ629636A true NZ629636A (en) | 2017-02-24 |
Family
ID=49083313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ629636A NZ629636A (en) | 2012-03-02 | 2013-02-28 | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US8987318B2 (enExample) |
| EP (2) | EP2820013B9 (enExample) |
| JP (2) | JP6378630B2 (enExample) |
| KR (1) | KR102112879B1 (enExample) |
| CN (1) | CN104284893B (enExample) |
| AU (1) | AU2013225840B2 (enExample) |
| BR (1) | BR112014021515A2 (enExample) |
| CA (1) | CA2866113C (enExample) |
| CY (1) | CY1120742T1 (enExample) |
| DK (1) | DK2820013T3 (enExample) |
| ES (1) | ES2691079T3 (enExample) |
| HR (1) | HRP20181623T1 (enExample) |
| HU (1) | HUE040231T2 (enExample) |
| IL (1) | IL234413B (enExample) |
| LT (1) | LT2820013T (enExample) |
| MX (1) | MX361349B (enExample) |
| NZ (1) | NZ629636A (enExample) |
| PL (1) | PL2820013T3 (enExample) |
| PT (1) | PT2820013T (enExample) |
| RS (1) | RS57863B9 (enExample) |
| SG (2) | SG10201607345YA (enExample) |
| SI (1) | SI2820013T1 (enExample) |
| SM (1) | SMT201800630T1 (enExample) |
| TR (1) | TR201815013T4 (enExample) |
| WO (1) | WO2013130892A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201815013T4 (tr) | 2012-03-02 | 2018-11-21 | Ralexar Therapeutics Inc | Dermal hastalıkların, rahatsızlıkların ve koşulların tedavisi için karaciğer x reseptör (lxr) modülatörleri. |
| US9751869B2 (en) * | 2013-03-15 | 2017-09-05 | Bristol-Myers Squibb Company | LXR modulators |
| CN104151300B (zh) * | 2013-05-15 | 2018-07-13 | 中国医学科学院医药生物技术研究所 | 一组2,3-二取代的苯并喹唑啉类的肝x受体的激动剂及用途 |
| HRP20201054T1 (hr) | 2013-09-04 | 2021-01-08 | Ellora Therapeutics, Inc. | Modulatori receptora x jetre (lxr) |
| WO2015035027A1 (en) * | 2013-09-04 | 2015-03-12 | Alexar Therapeutics, Inc. | Liver x receptor (lxr) modulators |
| EP3091970B1 (en) | 2014-01-10 | 2020-10-28 | Rgenix, Inc. | Lxr agonists and uses thereof |
| WO2017115319A2 (en) | 2015-12-30 | 2017-07-06 | Consejo Nacional De Investigaciones Científicas Y Técnicas (Conicet) | Use of brassinosteroid analogs for the treatment of dermal disorders by selectively modulating liver x receptors (lxr) and dermal disease treatment by brassinosteroid analogs acting as selective liver x receptor (lxr) modulators |
| JP7025022B2 (ja) | 2016-01-11 | 2022-02-24 | ザ ロックフェラー ユニバーシティー | 骨髄系由来抑制細胞関連障害の治療のための方法 |
| EP3713575A4 (en) | 2017-11-21 | 2021-08-25 | Rgenix, Inc. | POLYMORPHS AND THEIR USES |
| US20220257596A1 (en) | 2019-07-15 | 2022-08-18 | Novartis Ag | Methods for treating meibomian gland dysfunction with liver x receptor agonists |
| PL4073025T3 (pl) | 2019-12-13 | 2024-09-16 | Inspirna, Inc. | Sole metali i ich zastosowania |
| WO2022249006A1 (en) * | 2021-05-24 | 2022-12-01 | Novartis Ag | Use of 1,2,4-oxadiazole derivatives as liver x receptor agonists |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1199771A (en) * | 1915-07-01 | 1916-10-03 | Bates Valve Bag Co | Wire-twisting machine. |
| JP2004509161A (ja) | 2000-09-18 | 2004-03-25 | グラクソ グループ リミテッド | Ｌｘｒのアゴニストとして有用な置換アミノプロポキシアリール誘導体 |
| AUPR738301A0 (en) | 2001-08-30 | 2001-09-20 | Starpharma Limited | Chemotherapeutic agents |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| MXPA04011691A (es) | 2002-05-24 | 2005-09-12 | Pharmacia Corp | Moduladores del receptor x anilino hepaticos. |
| US6822120B2 (en) | 2002-05-24 | 2004-11-23 | Pharmacia Corporation | Sulfone liver X-receptor modulators |
| EP1572660B1 (en) | 2002-12-20 | 2011-01-26 | X-Ceptor Therapeutics, Inc. | Isoquinolinone derivatives and their use as therapeutic agents |
| JP2006193426A (ja) | 2003-09-05 | 2006-07-27 | Sankyo Co Ltd | 置換された縮環ピリミジン−４（３ｈ）−オン化合物 |
| WO2005113499A1 (ja) | 2004-05-20 | 2005-12-01 | Sankyo Company, Limited | インドール化合物 |
| WO2006003923A1 (ja) | 2004-06-30 | 2006-01-12 | Sankyo Company, Limited | 置換ベンゼン化合物 |
| BRPI0514017A (pt) | 2004-08-03 | 2008-05-27 | Wyeth Corp | indazóis úteis no tratamento de doenças cardiovasculares |
| US20070060589A1 (en) * | 2004-12-21 | 2007-03-15 | Purandare Ashok V | Inhibitors of protein arginine methyl transferases |
| WO2006109633A1 (ja) | 2005-04-07 | 2006-10-19 | Daiichi Sankyo Company, Limited | 置換インドール化合物 |
| US7213797B2 (en) | 2005-05-20 | 2007-05-08 | Garland Jerome Gaskins | Deck board straightener |
| US8569352B2 (en) | 2005-06-27 | 2013-10-29 | Exelixis Patent Company Llc | Imidazole based LXR modulators |
| SG162803A1 (en) * | 2005-06-27 | 2010-07-29 | Exelixis Inc | Imidazole based lxr modulators |
| DK1940786T3 (da) | 2005-09-16 | 2010-11-08 | Arrow Therapeutics Ltd | Biphenylderivater og deres anvendelse ved behandling af hepatitis C |
| WO2007034279A2 (en) | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | C3a antagonists and pharmaceutical compositions thereof |
| US20090062260A1 (en) | 2005-11-14 | 2009-03-05 | Irm Llc | Compounds and compositions as lxr modulators |
| EP1849781A1 (en) | 2006-04-28 | 2007-10-31 | Laboratorios del Dr. Esteve S.A. | Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments |
| TW200825054A (en) | 2006-10-18 | 2008-06-16 | Wyeth Corp | Quinoline compounds |
| CN101679297B (zh) | 2006-12-08 | 2012-01-11 | 埃克塞利希斯股份有限公司 | Lxr和fxr调节剂 |
| US8338437B2 (en) * | 2007-02-28 | 2012-12-25 | Methylgene Inc. | Amines as small molecule inhibitors |
| JP2010527930A (ja) | 2007-05-18 | 2010-08-19 | ワイス・エルエルシー | キナゾリン化合物 |
| US20090069288A1 (en) | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
| CN101778831B (zh) | 2007-08-13 | 2014-08-20 | 霍夫曼-拉罗奇有限公司 | 哌嗪酰胺衍生物 |
| BRPI0822237A2 (pt) | 2007-12-21 | 2015-06-30 | Wyeth Llc | Compostos de imidazo [1,2-a] piridina |
| US20110034526A1 (en) | 2007-12-21 | 2011-02-10 | Wyeth Llc | Benzimidazole Compounds |
| US20120015988A1 (en) * | 2008-05-13 | 2012-01-19 | Boehringer Ingelheim International Gmbh | Sulfone Compounds Which Modulate The CB2 Receptor |
| US8063088B2 (en) | 2008-06-11 | 2011-11-22 | Hoffmann-La Roche Inc. | Imidazolidine derivatives |
| EP2352725A1 (en) | 2008-11-07 | 2011-08-10 | Wyeth LLC | Quinoxaline-based lxr modulators |
| JP2012509334A (ja) | 2008-11-19 | 2012-04-19 | ワイス・エルエルシー | 肝ｘ受容体（ｌｘｒ）モジュレーターとしての極性キナゾリン類 |
| AR074701A1 (es) | 2008-12-22 | 2011-02-02 | Schering Corp | Moduladores de gamma secretasa |
| WO2010096170A2 (en) * | 2009-02-19 | 2010-08-26 | President And Fellows Of Harvard College | Inhibition of trna synthetases and therapeutic applications thereof |
| WO2010096777A1 (en) | 2009-02-23 | 2010-08-26 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| AU2010254082B2 (en) | 2009-05-28 | 2015-01-29 | Exelixis, Inc. | LXR modulators |
| WO2011045415A2 (en) | 2009-10-15 | 2011-04-21 | Guerbet | New imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases |
| GB0919757D0 (en) | 2009-11-12 | 2009-12-30 | Johnson Matthey Plc | Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs |
| US8906943B2 (en) | 2010-08-05 | 2014-12-09 | John R. Cashman | Synthetic compounds and methods to decrease nicotine self-administration |
| JPWO2012020820A1 (ja) * | 2010-08-11 | 2013-10-28 | 大正製薬株式会社 | ヘテロアリール−ピラゾール誘導体 |
| WO2012027710A2 (en) | 2010-08-27 | 2012-03-01 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
| AR088728A1 (es) | 2011-03-25 | 2014-07-02 | Bristol Myers Squibb Co | Moduladores de lxr como prodroga de imidazol |
| TR201815013T4 (tr) | 2012-03-02 | 2018-11-21 | Ralexar Therapeutics Inc | Dermal hastalıkların, rahatsızlıkların ve koşulların tedavisi için karaciğer x reseptör (lxr) modülatörleri. |
| EP3626309B1 (en) | 2012-08-13 | 2023-03-08 | The Rockefeller University | Lxrbeta agonist for the treatment of cancer |
| WO2015035027A1 (en) | 2013-09-04 | 2015-03-12 | Alexar Therapeutics, Inc. | Liver x receptor (lxr) modulators |
| HRP20201054T1 (hr) | 2013-09-04 | 2021-01-08 | Ellora Therapeutics, Inc. | Modulatori receptora x jetre (lxr) |
-
2013
- 2013-02-28 TR TR2018/15013T patent/TR201815013T4/tr unknown
- 2013-02-28 CN CN201380018482.7A patent/CN104284893B/zh not_active Expired - Fee Related
- 2013-02-28 CA CA2866113A patent/CA2866113C/en not_active Expired - Fee Related
- 2013-02-28 SG SG10201607345YA patent/SG10201607345YA/en unknown
- 2013-02-28 EP EP13754329.4A patent/EP2820013B9/en active Active
- 2013-02-28 ES ES13754329.4T patent/ES2691079T3/es active Active
- 2013-02-28 MX MX2014010537A patent/MX361349B/es active IP Right Grant
- 2013-02-28 SM SM20180630T patent/SMT201800630T1/it unknown
- 2013-02-28 AU AU2013225840A patent/AU2013225840B2/en not_active Ceased
- 2013-02-28 PL PL13754329T patent/PL2820013T3/pl unknown
- 2013-02-28 RS RS20181179 patent/RS57863B9/sr unknown
- 2013-02-28 HR HRP20181623TT patent/HRP20181623T1/hr unknown
- 2013-02-28 LT LTEP13754329.4T patent/LT2820013T/lt unknown
- 2013-02-28 JP JP2014560060A patent/JP6378630B2/ja not_active Expired - Fee Related
- 2013-02-28 HU HUE13754329A patent/HUE040231T2/hu unknown
- 2013-02-28 SI SI201331198T patent/SI2820013T1/sl unknown
- 2013-02-28 KR KR1020147027825A patent/KR102112879B1/ko not_active Expired - Fee Related
- 2013-02-28 WO PCT/US2013/028438 patent/WO2013130892A1/en not_active Ceased
- 2013-02-28 BR BR112014021515-4A patent/BR112014021515A2/pt active Search and Examination
- 2013-02-28 NZ NZ629636A patent/NZ629636A/en not_active IP Right Cessation
- 2013-02-28 PT PT13754329T patent/PT2820013T/pt unknown
- 2013-02-28 DK DK13754329.4T patent/DK2820013T3/en active
- 2013-02-28 SG SG11201405378VA patent/SG11201405378VA/en unknown
- 2013-02-28 EP EP18182346.9A patent/EP3441390A1/en not_active Withdrawn
-
2014
- 2014-09-01 IL IL234413A patent/IL234413B/en active IP Right Grant
- 2014-09-02 US US14/474,490 patent/US8987318B2/en not_active Expired - Fee Related
-
2015
- 2015-02-12 US US14/621,255 patent/US9637481B2/en not_active Expired - Fee Related
-
2017
- 2017-04-03 US US15/477,140 patent/US20170334897A1/en not_active Abandoned
-
2018
- 2018-04-18 US US15/956,389 patent/US20180370959A1/en not_active Abandoned
- 2018-08-02 JP JP2018145589A patent/JP6800922B2/ja not_active Expired - Fee Related
- 2018-10-08 CY CY181101037T patent/CY1120742T1/el unknown
-
2020
- 2020-05-13 US US15/931,403 patent/US20210101895A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ629636A (en) | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions | |
| PL2947072T3 (pl) | 1-(3-(6,7-dimetoksychinazolin-4-yloksy)fenylo)-3-(5-(1,1,1-trifluoro-2-metylopropan-2-ylo)izoksazol-3-ilo)mocznik jako modulator kinazy RAF w leczeniu chorób nowotworowych | |
| CL2013000884A1 (es) | El compuesto (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino, modulador del factor de crecimiento de fibroblastos (fgf); composicion farmaceutica, util en el tratamiento del cancer. | |
| SI2576523T1 (sl) | Kristalinične oblike 4-(5-(3-kloro-5-(trifluorometil)fenil)-4,5-dihidro 5-(trifluorometil)-3-izoksazolil)-N-(2-okso-2-((2,2,2-trifluoroetil) amino)etil)-1 naftalenkarboksamida | |
| JO3392B1 (ar) | مركبات عطرية حلقية غير متجانسة كمركبات مضادة للالتهاب | |
| NZ595553A (en) | VINYL INDAZOLYL COMPOUND; (E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol | |
| CL2012003358A1 (es) | Compuestos derivados de n-((het) arilalquil)) pirazol (tio) carboxamidas; composicion fungicida; metodo para controlar los hongos fitopatógenos de los cultivos. | |
| SI2785711T1 (sl) | 2-(fenil ali pirid-3-il)aminopirimidinski derivati kot modulatorji kinaze LRRK2 za zdravljenje Parkinsonove bolezni | |
| DK2878598T3 (da) | Krystallinsk form af 4-[5-(pyridin-4-yl)-1h-1,2,4-triazol-3-yl]pyridin-2-carbonitril | |
| IL206470A (en) | 2-Amino-1 - ((Phosphonooxy) Methyl) -3 - (3 - ((4 - ((2-Pyridinyloxy) Methyl) Phenyl) Methyl) -5-Isoxazolyl) - Pyridinium and Pharmaceutical Preparation Containing It | |
| DK3252069T3 (da) | (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentalfuoromethyl)estra-4,9-dien-3-oner til behandling af sygdomme | |
| CY1111701T1 (el) | Υδροχλωρικο αλας του 5-[3-(3-υδροξυφαινοξυ)αζετιδιν-1-υλ]-5-μεθυλ-2,2-διφαινυλεξαναμιδιου | |
| IL225704A (en) | Polymorphs and salts of 6– (1 h– indole – 4 – ram) –4– (5 - {[4– (1-methylethyl) –1 – piperazine] methyl} –1,3 – oxazole – 2 – ram) –1 h- Indazole as pi3k inhibitors for use in treating respiratory problems | |
| RU2017120217A (ru) | 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1 | |
| FR2927086B1 (fr) | Utilisation d'un melange exothermique pour la fabrication d'un enrobe bitumineux. | |
| MX379709B (es) | Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil] etoxi]fenil]metil]-2,4-tiazolidindiona y sus sales. | |
| EA201490960A1 (ru) | Состав 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамид с немедленным высвобождением | |
| UA98158U (uk) | Фторфенілпохідні 1,2,4-триазол-3-тіолів, що проявляють аналгетичну активність | |
| PT2943488T (pt) | Formas de sal de meglumina do ácido 2-((1r,4r)-4-(4-(5- (benzoxazol-2-ilamina)piridin-2-il)fenil)ciclohexil) acético e sua utilização como inibidores de dgat1 | |
| MX354518B (es) | Derivado de 6-oxo-1, 6-dihidro-piridazina para uso en el tratamiento de carcinoma hepatocelular (hcc). | |
| BR112017012558A2 (pt) | Composições de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h- indazol-5-il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il) fenil)-3,6-diidropiridin-1(2h)-il)-2-oxoetil)-3-(metiltio) pirrolidina-3-carboxamida para preparações farmacêuticas | |
| NZ599855A (en) | Carboxy oxazole or thiazole compounds as dgat - 1 inhibitors useful for the treatment of obesity | |
| UA88441U (en) | Methyl 2-((5-(3,4,5-trimethoxyphenyl)-1h-1,2,4-triazole-3-yl)thio)acetate exhibiting antihypoxic activity | |
| UA117756C2 (uk) | Застосування магнію n'-(2-(5-((теофілін-7'-іл)метил)-4-феніл-4н-1,2,4-триазол-3-іл)тіо)ацетату, що проявляє антимікробну активність | |
| UA108688C2 (ru) | Применение 2-(5- (3,4,5-триметоксифенил)-1н-1,2,4-триазол-3-илтио)ацетатной кислоты как антиоксидантного средства |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 28 FEB 2020 BY SHELSTON IP PTY LTD Effective date: 20170531 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 FEB 2021 BY COMPUTER PACKAGES INC Effective date: 20200418 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 FEB 2022 BY COMPUTER PACKAGES INC Effective date: 20210813 |
|
| LAPS | Patent lapsed |